Source - SMW
If you are looking for some new investment ideas for 2018, then come along to the Shares and AJ Bell Investor Evening in Manchester on Tuesday 20 February 2018. Directors from London Stock Exchange listed companies will present their latest plans regarding development and growth.

The event will take place close to the City Centre at the Macdonald Manchester Hotel (London Road, Manchester M1 2PG) which is easily accessible by road, tram and rail. Registration begins at 17.45 and presentations at 18.15. Those attending include private investors, analysts, brokers, wealth managers, fund managers, financial institutions as well as online and print press. 

ANGLE (AGL) is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).

ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood - even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.

The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:

Early detection of cancer;

Personalised cancer treatment;

Monitoring of cancer patients during treatment; and

Post-treatment monitoring of cancer patients in remission.



Presentations from: 

Andrew Newland, Chief Executive - ANGLE

Kiran Morzaria, Director & CEO - Cadence Minerals (KDNC)

Brian Stockbridge, CEO - First Sentinel

Charles Tatnall, Executive Chairman - Plutus PowerGen

Dave Mutton, Chief Operating Officer - PrimaryBid

SkinBioTherapeutics



Sponsored by:   AJ Bell Youinvest

PrimaryBid

Shareholders and potential investors can register now for free at: http://www.sharesmagazine.co.uk/events    


At 9:33am: (LON:AGL) Angle PLC share price was 0p at 51.5p